September 27 – 6:00 p.m. CEST / 12:00 p.p. ET: Live educational program on molecular gene expression testing
Register here
PROSIGNA PRODUCT INSERTS AND MSDS
-
Download the Prosigna Product Insert
-
Download the Prosigna Assay Brochure
-
Download the nCounter
Hybridization Buffer MSDS -
Download the nCounter Prep
Plate MSDS -
Download the nCounter
Reporter CodeSet MSDS -
Download the nCounter
Cartridge MSDS -
Download the nCounter DX
Analysis System User Manual -
Download the Prosigna
Product Data Sheet -
Download the RNA Reference Samples and Training Samples Datasheet
PROSIGNA REPORTS AND FORMS
-
Download the Annotated
Prosigna Patient Report
Scientific Evidence Of The Prosigna Assay’s Clinical Performance
More comprehensive information for better treatment decisions
-
Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
READ MORE
-
OPTIMA (Optimal Personalised
Treatment of early breast cancer using Multi-parameter Analysis) Clinical Trial
READ MORE
-
EXPERT (Examining
Personalised Radiation Therapy
for Low-risk Early Breast
Cancer) Clinical Trial
READ MORE
-
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensREAD MORE
-
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
READ MORE
-
Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer
READ MORE
-
Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy aloneREAD MORE
-
The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer
READ MORE
-
Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence ScoreREAD MORE
-
PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer
READ MORE
-
Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancerREAD MORE
-
The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancerREAD MORE
-
Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype- Prosigna® Test in the management of early-stage breast cancers
READ MORE
-
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (NICE Diagnostic Guidance)
READ MORE
-
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor–Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical TrialREAD MORE
-
Molecular Divers of Onco Type DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
READ MORE
-
OPTIMA (Optimal Personalized
Treatment of early breast cancer using Multi-parameter Analysis) Clinical Trial
READ MORE
PROSIGNA CENTERS
Select your country below to learn more about how you can have the Prosigna breast cancer assay performed on the locally available nCounter Dx Analysis System.
-
Australia
-
Sonic Genetics
Level 17, Grosvenor Place,
225 George Street
NSW 2000
Sydney800-010-447 (Australia only)
800-515-119 -
Bio-strategy
PO Box 14
VIC 3061, Campbellfield+ 61 3 9355 3900
www.bio-strategy.com
-
-
Denmark
-
Prosigna is covered by all
Health Care Regions in Denmark
-
-
France
-
Institut Claudius Regaud
1, Avenue Irène Joliot-Curie
Toulouse cedex 9 31059+ 33 (0) 5 31 15 50 50 (Standard)
33 (0) 5 31 15 52 01 -
Institut Curie
26, Rue d’Ulm
Paris 75005+ 33 (0) 1 56 24 55 00 (Standard)
-
Centre Jean-Perrin
58, rue Montalembert
Clermont-Ferrand 63011+ 33 (0) 4 73 27 80 80 (Standard)
+ 33 (0) 4 73 27 81 67 -
Centre Henri Becquerel
1, Rue d’Amiens
Rouen 76038+ 33 (0) 2 32 08 29 75
+ 33 (0) 2 32 08 22 22 -
Centre Oscar Lambret
3, Rue Frédéric Combemale
Lille 59000+ 33 (0) 3 20 29 59 48
-
Hospices Civils de Lyon
165, Chemin du Grand Revoyet
Pierre Benite 69495+ 33 (0) 4 78 86 11 86
www.chu-lyon.fr
https://biobook.chu-lyon.fr/Home -
Centre Léon Bérard
Cheney B 2ème étage,
28 rue Laennec
Lyon Cedex 69373+ 33 (0)4 78 78 28 28
-
-
Germany
-
Center for Molecular Pathology (CMP), Institute of Pathology
Heidelberg University Hospital, Im Neuenheimer Feld 224
69120 Heidelberg
+49 6221 56-34096
-
MVZ für Histologie, Zytologie
und molekulare Diagnostik Trier GmbHMax-Planck-Str. 5
Trier 54296+49 (0)14 61 830
-
MVZ Pathologie, Zytologie
und Dermatologie Viersen GmbHGereonstrasse 14a
Viersen 41747+49 (0) 2162-351906
-
MVZ Prof. Dr. med. A. Niendorf Pathologie Hamburg-West GmbH
Lornsenstr. 4, 22767 Hamburg,
Postfach 501107
22711 Hamburg+49 (40) 413 0353 – 0
http://www.pathologie-hh-west.de/
-
Pathologisches Institut –
Universitätsklinikum ErlangenKrankenhausstraße 8-10
Erlangen 91054+49 (0)9131 85-22286
http://www.pathologie.uk-erlangen.de
-
University Hospital Tuebingen – Institute of Pathology and Neuropathology – General and Molecular Pathology
Liebermeisterstr. 2
72076 Tübingen
+49 (0) 7071 29 82266
-
-
Hong Kong
-
DeNovo Service Limited
18 / F, Block B, Vita Tower
29 Wong Chuk Hang Road
Wong Chuk Hang
Hong Kong
852-2523 1868852-2523-1021
-
-
Italy
-
Anatomia Patologica ASST
Sette-Laghi, Ospedale Macchi VareseVia O.Rossi 9
Varese (VA) 21100(+39) 0332 270601
-
ASUR Marche – Ospedale Generale
Di Macerata OU. 0f Anatomy – PathologyVia S. Lucia 2
Macerata (MC) 62100(+39) 073 325 724 60
-
IRCCS Fondazione Pascale Istituto Nazionale Tumori
Via Mariano Semmola 53
80131 Naples
(+39)081 59031767
-
U.O.C. Anatomia Patologica – Azienda Ospedaliera – Universitaria Senese
Via delle Scotte
6 53100 Siena
0577 233450 – 585850 -
Vanvitelli University Hospital
Via Luciano Armanni 5
Napoli (NA) 80138(+39) 081 5664004
-
-
Israel
-
Hadassah Medical Organization, Hadassah University Hospital
P.O.B 12000
Jerusalem 91120 IsraelTel: 972-2-6778864
Fax: 972-2-6778861
-
-
Lithuania
-
National Cancer Institute
Santariškių g. 1
Vilnius LT-08660+(85) 219 0924
https://www.uicc.org/membership/national-cancer-institute-lithuania
-
-
Mexico
-
Accesorios para Laboratorios S.A. de C.V. (ACCESOLAB)
San Francisco 105,
Colonia San Francisco Cuautlalpan,
Naucalpan de Juárez,
Estado de México,
C.P. 53569 México
+52 55 52500805
-
-
Portugal
-
Instituto Portuges de Oncologia
do Porto Francisco Gentil, E.P.E.
(IPO Porto)Rua Dr António Bernardino de Almeida, 865
Porto 4200-072+351 225 084 000
-
IPATIMUP Diagnósticos
Rua Julio Amaral Carvalho 45
Porto
4200-135+351-225 570 732
-
-
Spain
-
Anatomia Patológica,
Hospital Germans Trias I PujolCarretera de Canyet s/n
Badalona 08916+34 93 497 88 53
-
Biomedical Diagnostic Center –
Hospital ClinicC/ Villarroel 170
Barcelona 08036+34 93 227 54 00 ext 5472
-
Centro de Diagnóstico Biomédico,
Hospital Clínic
C/ Villarroel 170
Barcelona 08036
+34 93 227 54 00 ext 5472
-
Fundación Jiménez Díaz
Avda., Reyes Católicos, n 2
Madrid CP 28040+34 91 550 48 00
-
Hospital General Universitario
Gregorio MarañónC. Dr. Esquerdo 46
Madrid 28007+34 91 529 07 05
-
Hospital Universitario
12 de OctubreAvda de Córdoba, s/n
Madrid 28041+34 91 390 82 75
-
Hospital Universitario de Salamanca
Paseo de la Trancisión s/n
Salamanca 37007+34 92 329 11 00 Ext.: 55847 (Pathology)
+34 923 136 783www.saludcastillayleon.es/CASalamanca/es
-
IMIBIC – Hospital Universitario
Reina SofiaAv. Menendez Pidal, s/n
Córdoba 14004+34 95 7213 759
-
Laboratorio de Biología
Molecular del Cáncer. Centro de
Investigaciones Médico-SanitariasC/ Marqués de Beccaria, 3
Málaga 29010+34 952 13 75 61/62
-
Oncogenomics SL
C/Arturo Soria 17
Madrid 28027+34 607 95 68 20
-
Pangaea Oncology S.A.
Sabino Arana 5
Barcelona 08028+34 93 546 01 40
-
SYNLAB Diagnósticos Globales
Carrer Verge de Guadalupe 18
Barcelona 08950+34 933 63 60 00
-
-
Sweden
-
Unilabs Pathology Huvudsta
Anderstorpsvägen 16,
second floor,
Solna, Stockholm 1715446732598273
-
-
Turkey
-
Acıbadem University
Kayışdağı Cad.
No:32 Ataşehir
Istanbul+0216 661 46 47
+0533 693 91 01
-
HEALTH INSURANCE COVERAGE
The Prosigna test is covered by an increasing number of public healthcare systems across the world. In Europe Prosigna is backed by leading Health Technology Assessment (HTA) agencies and/or decision makers such as:
- France – Haute Autorité de Santé (HAS)
- Germany – Gemeinsamer Bundesausschuss (G-BA)
- Italy – Ministero della Salute
- Sweden – TLV (Tandvårds- och Läkemedelsformånsverket) ordered by the Medical Products Council (MTP-rådet)
- United Kingdom – National Institute for Health and Care Excellence (NICE)
Prosigna is also reimbursed in Denmark, Israel and Spain.
To find out if the Prosigna test is covered in your country and for more information on your reimbursement status or private insurance options, please get in touch with our customer care team.
-
For Europe, Middle East and Africa, please contact us.
-
For Canada, Latin America and Oceania, please contact us.
VIDEOS
-
Differences between 1st and 2nd generation gene expression profile tests: which perform best and why?How do you do a direct comparison of prognostic performance across multiple molecular gene expression assays? To learn more, we invite you to watch this presentation of Dr. Ivana Sestak at SFSPM 2021 on molecular gene expression assays used to guide treatment of HR+ early-stage cancer. (English) -
Clinical evidence of molecular subtypes as prognostic and predictive value in HR+/Her2- breast cancers with or without lymph nodesSFSPM 2021, Marie-Ange Mouret-Reynier talks about molecular gene expression assays integrated into the patient pathway: new clinical data and feedback in France. (French) -
Real world multicenter study on the use of Prosigna® in France: therapeutic and economic impactsRoman Rouzier presents at SFSPM 2021 the outcome of a real-world multicenter study on the use of Prosigna Breast Cancer Assay in France and analyzes the therapeutic and economic impacts (French).This French study highlighted:
- The utility of Prosigna in real-world setting
- Prosigna beneficial budgetary impact in France
- Prosigna provides more information than other gene expression profile tests
-
Association of Breast Surgery (ABS) - Veracyte Sponsored EventWe invite you to watch this panel discussion and case study presentation on the Prosigna® Breast Cancer Prognostic Gene Signature Assay with:- Professor Mark Beresford – Clinical Oncologist
- Dr Marina Parton – Medical Oncologist
- Dr Judy King – Medical Oncologist
- Professor Abeer Shaaban – Breast Pathologist
- Mr James Harvey – Breast Surgeon
-
Veracyte Symposium – Genomic testing in breast cancer – more precision medicine?This Veracyte symposium was recorded at the SweBCG SOTA meeting, October 2021, Malmö, Sweden.- Swedish guidelines for testing in breast cancer and experiences from Stockholm – Prof. Johan Hartman, Karolinska Institutet
- Risk of recurrence and clinical utility of luminal subtypes – Prof Matthew J. Ellis, Baylor College of Medicine
- Next level personalized treatment decisions – the OPTIMA trial – Prof Robert Stein, University College London